For research use only. Not for therapeutic Use.
DCPT1061 potently inhibits PRMT1, PRMT6 and PRMT8 in vitro with less inhibitory effect on PRMT3, PRMT4, and PRMT5 or other epigenetic enzymes. DCPT1061 has antitumor effect[1][2].
| Catalog Number | I040153 |
| CAS Number | 2289726-31-2 |
| Synonyms | N’-[[2-(2,3-dichlorophenoxy)phenyl]methyl]-N,N’-dimethylethane-1,2-diamine |
| Molecular Formula | C17H20Cl2N2O |
| Purity | ≥95% |
| InChI | InChI=1S/C17H20Cl2N2O/c1-20-10-11-21(2)12-13-6-3-4-8-15(13)22-16-9-5-7-14(18)17(16)19/h3-9,20H,10-12H2,1-2H3 |
| InChIKey | GCURTAFSSBAXNO-UHFFFAOYSA-N |
| SMILES | CNCCN(C)CC1=CC=CC=C1OC2=C(C(=CC=C2)Cl)Cl |
| Reference | [1]. Jianfeng Wang, et al. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics. 2021 Mar 12;11(11):5387-5403. [2]. Hongru Tao, et al. PRMT1 inhibition activates the interferon pathway to potentiate antitumor immunity and enhance checkpoint blockade efficacy in melanoma. Cancer Res. 2023 Nov 22. |
